LIA
AZN icon

Lynx Investment Advisory’s AstraZeneca AZN Stock Holding History

Lynx Investment Advisory’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Buy
2,144
+898
+72% +$169K 0.13% 156
2026
Q1 		$246K Buy
1,246
+12
+1% +$2.31K 0.12% 163
2025
Q4 		$227K Buy
+1,234
New +$216K 0.12% 152
2024
Q4 		– Sell
-1,393
Closed -$217K – 147
2024
Q3 		$217K Buy
1,393
+53
+4% +$8.55K 0.16% 137
2024
Q2 		$209K Buy
+1,340
New +$202K 0.15% 126

Other funds holding AZN

EPGL
Evelyn Partners Group Ltd London $46.9B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Lynx Investment Advisory's AZN Position: Q2 2026 in Review

Lynx Investment Advisory increased its AstraZeneca (AZN) stake by 72% in Q2 2026, buying an estimated $169K and bringing the position to 2,144 shares worth $407K. The position accounts for 0.13% of the portfolio, ranked #156.

Lynx Investment Advisory first reported a position in AZN in Q2 2024 and has held it in 5 quarters since. 906 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Lynx Investment Advisory held 2,144 shares of AstraZeneca worth $407K as of Q2 2026.
  • Lynx Investment Advisory bought 898 AstraZeneca shares in Q2 2026, an estimated $169K.
  • AstraZeneca made up 0.13% of Lynx Investment Advisory's portfolio in Q2 2026, its #156 holding.
  • Lynx Investment Advisory first reported a position in AstraZeneca in Q2 2024 and has held it in 5 quarters since.
  • 906 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Lynx Investment Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.